Hyperarousal Helps Normalize Sleep in Individuals with Frequent Nightmares


In a new study, investigators find individuals suffering from frequent nightmare experience a lower amount of slow-wave sleep.

Borbala Blaskovich

Borbala Blaskovich

Frequent nightmares could be an indicator that an individual has increased high-frequency spectral power during NREM and pre-REM sleep periods.

A team, led by Borbala Blaskovich, Department of Translational Research in Psychiatry at the Max Planck Institute of Psychiatry, examined sleep architecture and electroencephalographic markers related to sleep regulations and hyperarousal in patients with frequent nightmares.

The study included 22 patients with frequent nightmare problems, as well as 22 healthy control participants. The 2 groups had a similar distribution of age, gender, and dream recall frequency.

It is well known that frequent nightmares have a high prevalence and constitute a risk factor for psychiatric conditions. However, the pathophysiology of frequent nightmares is poorly understood.

In the study, both the patients suffering from frequent nightmares and a healthy control group spent 2 consecutive nights in a sleep laboratory. The investigators evaluated the second night spectral power during NREM to REM sleep (pre-REM), REM to NREM transitions (Post-REM), and during NREM and REMN periods for both groups.

There were significant differences between the 2 groups in the pre-REM to post-REM changes in low- and high-frequency domains. The frequent nightmare individuals also experienced a lower amount of slow-wave sleep with increased beta and gamma power during the NREM and pre-REM periods.

There were no difference present during REM and post-REM phases.

While increased pre-REM high-frequency power could be driven by PTSD symptom intensity, decreased low-frequency activity still occurred regardless of the severity of PTSD symptoms.

“Our findings indicate that [nightmare] participants had increased high-frequency spectral power during NREM and pre-REM periods, as well as relatively reduced slow frequency and increased fast frequency spectral power across pre-and post-REM periods,” the authors wrote. “This combination of reduced sleep-protective activity and increased hyperarousal suggests an imbalance between sleep regulatory and wake-promoting systems in [nightmare] participants.”

Sleep disturbance is known as a cause a multitude of problems, impacting the body’s immune system and increasing the risk factors for depression, cancer, infection, hypertension, weight gain, heart disease, diabetes, inflammation, osteoporosis, chronic pain, and arrhythmias.

Nightmare duration is significantly associated with suicide risk independent of severity of current nightmares.

Insomnia symptoms and nightmare duration are significantly related to suicide risk after controlling for depressive symptoms, anxiety symptoms, PTSD symptoms, current insomnia, and current nightmares.

People who have a history of suicide attempts show lower sleep efficiency (the ratio of time asleep over time in bed trying to go to sleep).

Recently, investigators from Augusta University found a common drug that treats short-term sleeping problems could reduce suicidal ideation in patients with severe insomnia symptoms.

In the eight-week, three-site, double-blind, placebo-controlled parallel-group, randomized controlled trial that zolpidem (zolpidem-CR) hypnotic therapy in conjunction with an open-label selective serotonin reuptake inhibitor could be beneficial for suicidal outpatients with severe insomnia.

The study included 103 medication-free patients from 18-65-years old with major depressive disorder, insomnia, and suicidal ideation. A total of 51 patients in the study received zolpidem-CR, while 52 received a placebo.

The investigators found that the drug had a robust anti-insomnia effect, particularly for the patients with the most severe symptoms.

They did not observe a substantial treatment effect on the Scale for Suicide Ideation (95% CI, -2.19 to 1.08), but the reduction in scores was significantly positive related to improvement in insomnia after accounting for the effect of other depression symptoms.

The C-SSRS score was a different story. This score indicated that the medication had a significant impact (95% CI,−.50 to −.02).

They also found that the impact of zolpidem-CR was greater in reducing suicidal ideation on the C-SSRS in patients with more severe insomnia.

The study, “Cortical hyperarousal in NREM sleep normalizes from pre- to post- REM periods in individuals with frequent nightmares,” was published online in Sleep.

Related Videos
Nancy Foldvary-Schaefer, DO, MS: New Guidance for REM Sleep Behavior Disorder
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
John Harsh, PhD
Reena Mehra, MD: Biomarkers and Endophenotypes for Personalized Patient Care
Reena Mehra, MD: Exploring Endophenotypes for Predicting Clinical Sleep Outcomes
Reena Mehra, MD, MS
© 2024 MJH Life Sciences

All rights reserved.